Style de citation APA

Chen, Y., Li, F., Li, D., Liu, W., & Zhang, L. (2021). Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway. Clinical immunology (Orlando, Fla.), 227, 108728. https://doi.org/10.1016/j.clim.2021.108728

Style de citation Chicago

Chen, Ying, Fangxuan Li, Dan Li, Wenxin Liu, et Lei Zhang. "Atezolizumab and Blockade of LncRNA PVT1 Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via JAK2/STAT3/PD-L1 Pathway." Clinical Immunology (Orlando, Fla.) 227 (2021): 108728. https://dx.doi.org/10.1016/j.clim.2021.108728.

Style de citation MLA

Chen, Ying, et al. "Atezolizumab and Blockade of LncRNA PVT1 Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via JAK2/STAT3/PD-L1 Pathway." Clinical Immunology (Orlando, Fla.), vol. 227, 2021, p. 108728.